Pulik Łukasz, Łęgosz Paweł, Motyl Gabriela
Department of Orthopedics and Traumatology, Medical University of Warsaw, Poland.
Scientific Association of Reconstructive and Oncological Orthopedics of the Department of Orthopedics and Traumatology, Medical University of Warsaw, Poland.
Reumatologia. 2023;61(3):191-201. doi: 10.5114/reum/168503. Epub 2023 Jul 2.
Although the pathological mechanisms involved in osteoarthritis (OA) and rheumatoid arthritis (RA) are different, the onset and progression of both diseases are associated with several analogous clinical manifestations, inflammation, and immune mechanisms. In both diseases, cartilage destruction is mediated by matrix metalloproteinases (MMPs) synthesized by chondrocytes and synovium fibroblasts. This review aims to summarize recent articles regarding the role of MMPs in OA and RA, as well as the possible methods of targeting MMPs to alleviate the degradation processes taking part in OA and RA. The novel experimental MMP-targeted treatments in OA and RA are MMP inhibitors eg. 3-B2, taraxasterol, and naringin, while other treatments aim to silence miRNAs, lncRNAs, or transcription factors. Additionally, other recent MMP-related developments include gene polymorphism of MMPs, which have been linked to OA susceptibility, and the MMP-generated neoepitope of CRP, which could serve as a biomarker of OA progression.
尽管骨关节炎（OA）和类风湿关节炎（RA）所涉及的病理机制不同，但这两种疾病的发病和进展都与一些类似的临床表现、炎症和免疫机制有关。在这两种疾病中，软骨破坏均由软骨细胞和成纤维细胞合成的基质金属蛋白酶（MMPs）介导。本综述旨在总结近期有关MMPs在OA和RA中的作用的文章，以及靶向MMPs以减轻参与OA和RA的降解过程的可能方法。OA和RA中新型的靶向MMPs的实验性治疗方法是MMP抑制剂，例如3 - B2、蒲公英甾醇和柚皮苷，而其他治疗旨在使miRNA、lncRNA或转录因子沉默。此外，近期其他与MMPs相关的进展包括与OA易感性相关的MMPs基因多态性，以及可作为OA进展生物标志物的MMPs产生的C反应蛋白新表位。
